Novartis wins FDA approval for Fabhalta, the first treatment for C3 glomerulopathy
Novartis secures FDA approval for Fabhalta, the first-ever treatment for C3G. Find out how this breakthrough impacts patients and investors. Read More
Humana expands value-based care with new cancer and kidney disease initiatives
Humana Inc., a leading health and well-being company, has reinforced its commitment to value-based care by introducing two major healthcare initiatives. The company has announced ... Read More
Hypertension: Understanding the causes, symptoms, and effective management
Hypertension, commonly known as high blood pressure, is a chronic condition where the force of blood against the artery walls is persistently elevated. While often ... Read More
FDA grants Otsuka’s Sibeprenlimab breakthrough therapy designation in IgAN
In a significant development for the treatment of kidney disease, the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to sibeprenlimab, an ... Read More
Novartis acquires kidney disease innovator Chinook Therapeutics
Swiss pharmaceutical giant Novartis has wrapped up the previously announced $3.5 billion acquisition of Seattle-based biopharmaceutical firm Chinook Therapeutics, Inc. This deal propels Novartis deeper ... Read More
FDA approves Gilead’s Veklury for COVID-19 patients with severe renal impairment
Gilead Sciences said that the US Food and Drug Administration (FDA) has approved a supplemental new drug application (sNDA) for Veklury (remdesivir) usage in COVID-19 ... Read More
ProKidney to acquire manufacturing facility in North Carolina for REACT commercial production
ProKidney, a late clinical-stage cellular therapeutics company, has announced plans to acquire a 210,000 square foot facility and approximately 22 acres of land in Greensboro, ... Read More
Novartis to expand renal portfolio with Chinook Therapeutics acquisition
Novartis has announced its agreement to acquire Chinook Therapeutics, a clinical stage biopharmaceutical company based in Seattle, Washington in a deal worth up to around ... Read More
AstraZeneca wraps up $1.8bn acquisition of CinCor Pharma
AstraZeneca has closed the previously announced $1.8 billion acquisition of US biopharmaceutical company CinCor Pharma. Under the terms of the agreement, AstraZeneca acquired all outstanding ... Read More
GSK gets Jesduvroq FDA approval for anaemia of chronic kidney disease
GSK has secured the approval of the US Food and Drug Administration (FDA) for the company’s Jesduvroq (daprodustat) for anaemia of chronic kidney disease (CKD) ... Read More